The consequences of liver fibrosis, in the short and long term

Learning that your liver has fibrosis, or that a score such as FIB-4 is high, raises a simple question: what does this change, now and later? The answer depends above all on the stage. Early fibrosis has almost no immediate consequence and can regress. Advanced fibrosis calls for follow-up, because over the years it exposes the liver to serious complications. This article describes both time horizons, without dramatizing and without minimizing.

It all depends on the stage

Fibrosis is a scar that forms in the liver when it is repeatedly injured. It is classified from F0 (no fibrosis) to F4 (cirrhosis). Stages F1 and F2 correspond to mild to moderate fibrosis. Stage F3 is advanced fibrosis. Stage F4, cirrhosis, is when scarring has reshaped the entire liver.

Consequences aren't proportional: they stay very low up to stage F2, then rise sharply from stage F3 onward. A 2021 American study published in the New England Journal of Medicine (Sanyal et al.) measured this in 1,773 adults with biopsy-confirmed steatosis. The rate of serious liver complications was 0.05 per 100 person-years at stages F0 to F2, 0.99 at stage F3, and 2.69 at stage F4.

In the short term: few signs, but a time to act

Usually, no symptoms at all

The liver has no pain-sensitive nerves in its tissue, and it has a large reserve: it keeps performing its functions even when a significant part of its tissue is scarred. Fibrosis, even advanced, therefore usually isn't felt. Some people describe fatigue, but this sign is too common to be a reliable clue on its own.

Routine blood panels can also stay normal. Transaminases don't reflect the degree of fibrosis, and tests that measure liver function, such as albumin or prothrombin time, only change at a late stage. This silence is why the disease is often found by chance, and why screening tools are needed.

Medical follow-up gets underway

The first concrete consequence of fibrosis is therefore medical. When a FIB-4 result isn't reassuring, the doctor offers a further test, most often elastography (FibroScan), which measures liver stiffness. Depending on the result, they look for the cause: alcohol, metabolic factors, hepatitis B and C, iron overload. If the risk is low, a follow-up check is simply scheduled one to three years later. If advanced fibrosis is confirmed, a hepato-gastroenterologist takes over.

A signal that goes beyond the liver

In people whose fibrosis is linked to steatosis, the first risk isn't liver-related. Cardiovascular disease remains their leading cause of death, and several studies have shown that a high FIB-4 is associated with greater cardiovascular risk. Finding fibrosis is therefore also an opportunity to check your blood pressure, cholesterol, and blood sugar. The What is my cardiovascular risk? and Do I have high blood pressure? tools can help with that check.

A window where everything is still possible

This is the most important short-term consequence, and it's a positive one: as long as fibrosis hasn't reached the cirrhosis stage, it can regress if the cause is treated. Reducing or stopping alcohol, losing weight, getting diabetes under control, or treating viral hepatitis allow the liver to resorb some of its scarring, over one to several years. In a study published in 2015 in Gastroenterology (Vilar-Gomez et al.), fibrosis had regressed in 45% of people who had lost at least 10% of their weight in one year.

In the long term: the risks of progressing fibrosis

Progression to cirrhosis

Without action on the cause, fibrosis can keep spreading. This progression is slow: with steatohepatitis, it takes an average of seven years to move from one stage to the next, according to a 2015 review (Singh et al.). It isn't inevitable either: some people remain stable for decades.

Cirrhosis is common and often goes unrecognized. In France, it affects between 2,000 and 3,300 people per million inhabitants and causes about 15,000 deaths a year, according to the French national professional council of hepato-gastroenterology. In the United States, chronic liver disease and cirrhosis were responsible for 52,274 deaths in 2024, making it the ninth leading cause of death according to the CDC. Worldwide, the Global Burden of Disease study attributes about 1.4 million deaths to it in 2021.

Compensated, then decompensated cirrhosis

Cirrhosis can stay “compensated” for a long time: the liver is heavily scarred, but it still performs its functions, and the person leads a normal life. Landmark work published in 2006 in the Journal of Hepatology (D'Amico et al.) estimates median survival at more than twelve years at this stage.

Complications appear when scarring hampers blood flow through the liver too much. Pressure then rises in the portal vein, which carries blood from the intestine to the liver: this is portal hypertension. Cirrhosis is called “decompensated” when the following occur:

• ascites, a build-up of fluid in the abdomen, the most common complication;
• gastrointestinal bleeding, from ruptured varices that form in the esophagus or stomach;
• hepatic encephalopathy, problems with memory, concentration, and alertness, linked to substances the liver can no longer clear;
• jaundice and greater susceptibility to infections.

This turning point changes the prognosis: in the same analysis, median survival was about two years after a first decompensation. Treatments exist, however, to prevent these complications — for example beta-blocker medications or variceal banding — and to treat them when they occur.

Liver cancer

Cirrhosis is the main setting for primary liver cancer, hepatocellular carcinoma: about 90% of these cancers develop on a cirrhotic liver, according to the Fondation ARC. In France, about 11,700 new cases were diagnosed in 2023, three-quarters of them in men, and the disease causes close to 8,700 deaths a year.

This is the reason for surveillance. In people with cirrhosis, a liver ultrasound is recommended every six months. According to the French Association for the Study of the Liver (AFEF), this regular screening reduces liver cancer mortality by about 40%, because it allows small tumors that are still treatable to be found. Without surveillance, the cancer is often found late, and five-year survival is then only around 15%.

Transplantation, as a last resort

When the liver can no longer perform its functions, or in cases of limited cancer, a liver transplant may be offered. More than a thousand liver transplants are performed each year in France. It's a major procedure, but its results are good, and it's a reminder that solutions exist even at the most advanced stages.

What really changes the outlook

The figures in the previous paragraphs describe what happens when the disease progresses without care. Three things change that trajectory.

The first is treating the cause. Stopping alcohol, controlling viral hepatitis, or losing weight reduce the risk of complications, even at the cirrhosis stage. In a study published in 2013 in The Lancet (Marcellin et al.), 74% of patients with hepatitis B-related cirrhosis no longer had it after five years of treatment.

The second is early detection. Fibrosis identified at stage F2 or F3 leaves years to act, while cirrhosis discovered through a complication leaves much less room.

The third is regular follow-up: twice-yearly ultrasounds in cases of cirrhosis, up-to-date vaccinations against hepatitis A and B, caution with certain medications, and attention to heart and blood vessel health.

What to remember

In the short term, fibrosis can't be seen or felt; its main consequence is opening a window in which it's possible to protect your liver. In the long term, if nothing changes, advanced fibrosis can progress to cirrhosis and its complications. In between, there is time — often a lot of it — and ways to act whose effectiveness is proven. A high FIB-4 result doesn't mean the liver is damaged: it means it's worth talking to your doctor, who can check.

To estimate your fibrosis risk from a blood test, take the “Is my liver damaged?” test.